Seres Therapeutics Updates Principal Executive Offices
Ticker: MCRB · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Seres Therapeutics (MCRB) filed an 8-K to update its corporate address, a minor administrative change.**
AI Summary
Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 30, 2024, to update its principal executive offices to 101 Cambridgepark Drive, Cambridge, MA 02140. This routine administrative change, while not directly impacting the company's financial performance or strategic direction, is important for investors as it ensures accurate contact information for the company, which trades on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).
Why It Matters
This filing is a routine administrative update of Seres Therapeutics' business address and does not indicate any operational or financial changes. It's important for maintaining accurate public records.
Risk Assessment
Risk Level: low — This filing is purely administrative, reporting a change of address, and carries no inherent financial or operational risk.
Analyst Insight
Smart investors would note this as a routine administrative update with no immediate impact on investment decisions. It's a non-event for stock performance.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — the registrant filing the 8-K
- MCRB (company) — the trading symbol for Seres Therapeutics, Inc.
- The Nasdaq Stock Market LLC (company) — the exchange where MCRB common stock is registered
- Cambridge (company) — city of the new principal executive offices
- MA (company) — state of the new principal executive offices
FAQ
What is the purpose of this 8-K filing by Seres Therapeutics, Inc.?
The purpose of this 8-K filing is to report a change in the principal executive offices of Seres Therapeutics, Inc. to 101 Cambridgepark Drive, Cambridge, MA 02140, as of January 30, 2024.
What is the new address for Seres Therapeutics, Inc. as reported in this filing?
The new address for Seres Therapeutics, Inc. is 101 Cambridgepark Drive, Cambridge, MA 02140, as stated in the filing.
What is the trading symbol and exchange for Seres Therapeutics, Inc.?
Seres Therapeutics, Inc. trades under the symbol MCRB on The Nasdaq Stock Market LLC (Nasdaq Global Select Market), as indicated in the filing.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 30, 2024.
Is this filing related to any financial or operational changes for Seres Therapeutics, Inc.?
No, this filing is categorized under 'Other Events' and specifically details a change in the company's business address, not financial or operational changes.
Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-01-30 16:01:57
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
Filing Documents
- d742357d8k.htm (8-K) — 24KB
- 0001193125-24-019398.txt ( ) — 139KB
- mcrb-20240130.xsd (EX-101.SCH) — 3KB
- mcrb-20240130_lab.xml (EX-101.LAB) — 17KB
- mcrb-20240130_pre.xml (EX-101.PRE) — 11KB
- d742357d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 30, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President